rusfertide
protagonist therapeutics
['mpnsm', '#mpn', 'rusfertide']
dr kremyanskaya et al. current standard of care therapy in pv does not consistency maintain hematocrit &lt;45%, thereby potentially increasing the risk of thromboembolic events. rusfertide has the potential to consistently maintain hematocrit &lt;45%. #eha2023 #mpnsm 
Senior researcher (@IKNL, @ErasmusMC, @AmsterdamUMC) leading population-based cancer research in the Netherlands. Tweets are my own. #leusm #lymsm #crypto #xrp